Search - tctmd.com

Displaying 1 - 20 of 72

Sort: Relevancy | Date

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Conference News EuroPCR 2016

Transradial PCI Shows Consistent Benefit in All ACS Patients: MATRIX Access

Michael O'Riordan

May 19, 2016

News Daily News

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

L.A. McKeown

March 08, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

L.A. McKeown

March 08, 2016

Presentation TCT 2015

The MATRIX of Antithrombin Alternatives: Pros and Cons

Presenter: George D. Dangas, Paul A. Gurbel, Marco Valgimigli

October 13, 2015

News Conference News TCT 2015

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Todd Neale

October 13, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Presenter: John A. Bittl, E. Magnus Ohman, Marco Valgimigli

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

Presentation ESC 2015

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Presenter: Marco Valgimigli

September 01, 2015

Advertisement

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Transradial PCI Shows Consistent Benefit in All ACS Patients: MATRIX Access

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

The MATRIX of Antithrombin Alternatives: Pros and Cons

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content